Capital Advantage’s Antares Pharma, Inc. ATRS Stock Holding History

Capital Advantage’s Portfolio ATRS Stock Details ATRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-13,000	Closed	-$45K	–	46
2021 Q4	$45K	Hold	13,000	–	–	0.01%	40
2021 Q3	$47K	Hold	13,000	–	–	0.01%	38
2021 Q2	$57K	Buy	+13,000	New	+$53K	0.01%	40
2021 Q1	–	Sell	-16,000	Closed	-$61K	–	114
2020 Q4	$61K	Hold	16,000	–	–	0.02%	105
2020 Q3	$51K	Hold	16,000	–	–	0.02%	92
2020 Q2	$44K	Sell	16,000 -8,000	-33%	-$22.3K	0.02%	90
2020 Q1	$66K	Hold	24,000	–	–	0.03%	87
2019 Q4	$96K	Sell	24,000 -10,000	-29%	-$40.9K	0.03%	94
2019 Q3	$114K	Buy	+34,000	New	+$112K	0.04%	88
2019 Q1	$103K	Hold	34,000	–	–	0.04%	77
2018 Q4	$92K	Hold	34,000	–	–	0.03%	71
2018 Q3	$114K	Hold	34,000	–	–	0.03%	81
2018 Q2	$88K	Hold	34,000	–	–	0.02%	81
2018 Q1	$75K	Hold	34,000	–	–	0.02%	73
2017 Q4	$68K	Hold	34,000	–	–	0.02%	78
2017 Q3	$110K	Buy	+34,000	New	+$105K	0.03%	81

Other funds holding ATRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Amundi Paris, France $367B AUM 31.23% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

Capital Advantage's ATRS Position: Q1 2022 in Review

Capital Advantage sold out of Antares Pharma, Inc. (ATRS) in Q1 2022, closing a stake of 13,000 shares — an estimated $45K sold.

Capital Advantage first reported a position in ATRS in Q3 2017 and held it in 16 quarters. The position peaked at $114K in Q3 2019. 177 funds tracked by Wall St. Rank hold ATRS as of Q1 2022.

Capital Advantage reported no remaining Antares Pharma, Inc. position as of Q1 2022 after selling out during the quarter.
Capital Advantage sold 13,000 Antares Pharma, Inc. shares in Q1 2022, an estimated $45K.
Capital Advantage first reported a position in Antares Pharma, Inc. in Q3 2017 and held it in 16 quarters.
Capital Advantage's Antares Pharma, Inc. position peaked at $114K in Q3 2019.
177 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q1 2022.

Based on Capital Advantage's 13F filing for Q1 2022, filed 10 May 2022.